Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert F Iii Williamson is Director at Perspective Therapeutics. OQRO lists 4 transactions filed with the SEC under this name, the latest on Apr 1, 2025, each linked to the official Form 4.
Director
Disclosures on record
4
Companies involved
1
2 buys, median +6.8 pts vs S&P 500, beat it 1 of 2 times.
Average +6.8 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 27, 2024 to Apr 1, 2025, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 50% of the 2 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Perspective TherapeuticsCATX
4 disclosures · Nov 2024 – Apr 2025 · 4 bought
Mar 31, 2025Bought~$82Kdisclosed Apr 1
DetailsOfficial recordMar 28, 2025Bought~$50Kdisclosed Apr 1
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Nov 25, 2024Bought~$13Kdisclosed Nov 27
DetailsOfficial recordNov 25, 2024Bought~$9.6Kdisclosed Nov 27
DetailsOfficial recordAs of the latest filing on , Robert F Iii Williamson reported holding 108,982 shares of Perspective Therapeutics (CATX), worth about $103K at the last close of $1 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Perspective Therapeutics CATX | 108,982 | 109K direct | $1 | $103K | Mar 31, 2025 |
Is this Robert F Iii Williamson’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Robert F Iii Williamson bought shares on the open market in 2023, 2024 and 2025.
Robert F Iii Williamson reported 24 open-market purchases and 0 sales since 2023; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $132K2×2 trades | — |
| 2024 | $333K19×19 trades | — |
| 2023 | $8.2K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 31, 2025, Robert F Iii Williamson reported holding 108,982 shares of Perspective Therapeutics (CATX). At the last close of $1 on Nov 13, 2026, that is about $103K. This is the stake disclosed in filings, not a net worth.
Robert F Iii Williamson bought shares on the open market in 2023, 2024 and 2025.
In SEC filings since 2023: the latest open-market purchase is from 2025; no open-market sale is on record.
Perspective Therapeutics (CATX), from 2023 to 2025: 24 purchases and 0 sales.
Robert F Iii Williamson reported 24 open-market purchases and 0 sales here, 2023 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
